Andreessen Horowitz and Lilly Unite to Launch Biotech Fund
Funding | Jan 10, 2025 | Andreessen Horowitz
Andreessen Horowitz (a16z) Bio + Health announced the creation of a $500 million Biotech Ecosystem Venture Fund in partnership with Eli Lilly and Company (Lilly). This first-of-its-kind fund aims to drive innovation in human health by investing in companies involved in developing new medicines and disease treatments. Managed by a16z, the fund will support companies at all stages of their growth, taking a long-term approach to enable disruptive healthcare and biotechnology advancements. Lilly offers deep life science R&D expertise and additional resources like Catalyze360, which provides support for biotech startups. This collaboration harnesses the strengths of both a16z and Lilly to overcome complex challenges in the healthcare sector, with the ultimate goal of delivering transformative therapies and care to patients.
Sectors
- Biotechnology
- Venture Capital
- Healthcare
Geography
- United States – Andreessen Horowitz and Eli Lilly, both US-based firms, are key players in this new Biotech Ecosystem Fund.
Industry
- Biotechnology – The article is centered on the creation of a Biotech Ecosystem Fund, highlighting investments in new medicines and treatment development.
- Venture Capital – Andreessen Horowitz is launching a venture capital fund to stimulate innovation in the biotech sector.
- Healthcare – The fund’s goal is transformative progress in healthcare through new therapeutic platforms and technologies.
Financials
- $500 million – The total capital allocated to the Biotech Ecosystem Venture Fund for investments.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Andreessen Horowitz (a16z) | Fund Manager | Company | A venture capital firm managing the Biotech Ecosystem Venture Fund. |
| Eli Lilly and Company | Partner and Contributor | Company | A pharmaceutical company partnering with a16z and contributing capital and resources. |
| Vineeta Agarwala, M.D., Ph.D. | General Partner | Person | A general partner at a16z Bio + Health, providing insights on the fund's objectives. |
| Nisha Nanda, Ph.D. | Group Vice President | Person | Leads Catalyze360 at Lilly, supporting biotech startup growth through the fund. |